Compare Adaptive Biotechnologies Corp (ADPT) vs The Coca-Cola Co K (KO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs The Coca-Cola Co K — how do they compare? Adaptive Biotechnologies Corp trades at $19.95 (market cap $3.33B), while The Coca-Cola Co K trades at $84.44 (market cap $361.62B). The key difference: The Coca-Cola Co K is far larger — about 108.6× Adaptive Biotechnologies Corp's market cap, and The Coca-Cola Co K pays a 2.52% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | KO | |
|---|---|---|
Market Cap | $3.33B | $361.62B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $84.14 |
52-Week Low | $10.24 | $65.67 |
Enterprise Value | $3.19B | $391.69B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Coca-Cola (KO) trades at $84.74, up 2.15% today, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported robust earnings, beating estimates for three consecutive quarters, with a net income margin of 27.8% in 2025. Recent news highlights steady demand and dividend reliability, with the stock near its consensus price target of $88.14.
KO offers a stable investment with consistent dividend growth and solid fundamentals, but faces risks from regional demand volatility and high valuation multiples. Analyst consensus is bullish, with 60% buy ratings, though the stock's current price proximity to resistance levels suggests limited near-term upside without new catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
